BRPI0911347A2 - gama lactamas substituídas como agentes terapêuticos - Google Patents

gama lactamas substituídas como agentes terapêuticos

Info

Publication number
BRPI0911347A2
BRPI0911347A2 BRPI0911347A BRPI0911347A BRPI0911347A2 BR PI0911347 A2 BRPI0911347 A2 BR PI0911347A2 BR PI0911347 A BRPI0911347 A BR PI0911347A BR PI0911347 A BRPI0911347 A BR PI0911347A BR PI0911347 A2 BRPI0911347 A2 BR PI0911347A2
Authority
BR
Brazil
Prior art keywords
gamma
therapeutic agents
substituted lactams
lactams
substituted
Prior art date
Application number
BRPI0911347A
Other languages
English (en)
Portuguese (pt)
Inventor
T Dinh Danny
W Old David
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0911347A2 publication Critical patent/BRPI0911347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911347A 2008-04-24 2009-04-22 gama lactamas substituídas como agentes terapêuticos BRPI0911347A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4750108P 2008-04-24 2008-04-24
PCT/US2009/041389 WO2009132088A1 (en) 2008-04-24 2009-04-22 Substituted gamma lactams as therapeutic agents

Publications (1)

Publication Number Publication Date
BRPI0911347A2 true BRPI0911347A2 (pt) 2018-03-20

Family

ID=40852537

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911347A BRPI0911347A2 (pt) 2008-04-24 2009-04-22 gama lactamas substituídas como agentes terapêuticos

Country Status (19)

Country Link
US (1) US7820661B2 (enExample)
EP (1) EP2291368B1 (enExample)
JP (1) JP5524181B2 (enExample)
KR (1) KR20110008263A (enExample)
CN (1) CN102076681A (enExample)
AU (1) AU2009239372B2 (enExample)
BR (1) BRPI0911347A2 (enExample)
CA (1) CA2722529A1 (enExample)
CO (1) CO6321273A2 (enExample)
DK (1) DK2291368T3 (enExample)
ES (1) ES2399314T3 (enExample)
IL (1) IL208899A0 (enExample)
MX (1) MX2010011636A (enExample)
MY (1) MY150518A (enExample)
PL (1) PL2291368T3 (enExample)
RU (1) RU2543379C2 (enExample)
UA (1) UA103616C2 (enExample)
WO (1) WO2009132088A1 (enExample)
ZA (1) ZA201007553B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
CA2534484A1 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8377984B2 (en) * 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2009236356A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2009249388B2 (en) * 2008-05-20 2014-04-03 Allergan, Inc. Therapeutic lactams
US20100204335A1 (en) * 2008-12-01 2010-08-12 Allergan, Inc. Kit and composition for eyelash growth
KR20180021919A (ko) 2009-11-09 2018-03-05 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
AU2013306012B2 (en) * 2012-08-21 2018-02-08 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US9540357B1 (en) 2014-07-31 2017-01-10 Allergan, Inc. 15-aryl prostaglandins as EP4 agonists, and methods of use thereof
JP6662864B2 (ja) * 2014-10-02 2020-03-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ガンマ−ラクタムのエステルプロドラッグ及びそれらの使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395798A (en) * 1889-01-08 reason
US4007210A (en) 1973-04-27 1977-02-08 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenylmethoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanates
US3985798A (en) 1975-01-27 1976-10-12 American Cyanamid Company 11α-HOMO-PROSTANOIC ACIDS AND ESTERS
US4060540A (en) 1975-09-18 1977-11-29 American Cyanamid Company Novel 3-triphenylmethoxy-1-alkynes, 3-triphenyl-methoxy-1-trans-alkenyl-dialkyl-alanes, and lithium 3-triphenylmethoxy-1-trans-alkenyl-dialkyl alanates
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE3876050T2 (de) 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5288754A (en) 1992-02-04 1994-02-22 Allergan, Inc. Polar C-1 esters of prostaglandins
US5721273A (en) 1993-12-15 1998-02-24 Alcon Laboratories, Inc. Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
DE60208568T2 (de) 2001-07-16 2006-10-05 F. Hoffmann-La Roche Ag Prostaglandinanaloga als ep4-rezeptoragonisten
WO2003040126A1 (en) 2001-11-05 2003-05-15 Allergan, Inc. φ-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS
TW200305425A (en) * 2002-03-05 2003-11-01 Ono Pharmaceutical Co 8-Azaprostaglandin derivatives and medicament containing same as active ingredient
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
BRPI0518563A2 (pt) * 2004-12-22 2008-11-25 Janssen Pharmaceutica Nv moduladores de delta-opiàide tricÍclicos
DK1856042T3 (da) * 2005-03-10 2012-09-17 Allergan Inc Substituerede gamma-lactamer som terapeutiske midler
WO2007005176A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2007109578A2 (en) * 2006-03-20 2007-09-27 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
KR101422305B1 (ko) 2006-08-11 2014-07-22 알러간, 인코포레이티드 치료학적 락탐
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
EP2121672B1 (en) * 2007-01-31 2014-12-10 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
WO2009132097A1 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
EP2291368B1 (en) 2012-12-19
AU2009239372A1 (en) 2009-10-29
MY150518A (en) 2014-01-30
MX2010011636A (es) 2010-11-25
KR20110008263A (ko) 2011-01-26
ES2399314T3 (es) 2013-03-27
US7820661B2 (en) 2010-10-26
IL208899A0 (en) 2011-01-31
UA103616C2 (ru) 2013-11-11
DK2291368T3 (da) 2013-03-18
JP5524181B2 (ja) 2014-06-18
CA2722529A1 (en) 2009-10-29
WO2009132088A1 (en) 2009-10-29
US20090270392A1 (en) 2009-10-29
CN102076681A (zh) 2011-05-25
AU2009239372B2 (en) 2013-09-19
JP2011518833A (ja) 2011-06-30
RU2010144637A (ru) 2012-05-27
ZA201007553B (en) 2011-08-31
PL2291368T3 (pl) 2013-05-31
RU2543379C2 (ru) 2015-02-27
EP2291368A1 (en) 2011-03-09
CO6321273A2 (es) 2011-09-20

Similar Documents

Publication Publication Date Title
BRPI0911347A2 (pt) gama lactamas substituídas como agentes terapêuticos
BRPI0916931A2 (pt) agentes terapêuticos
BRPI0922845A2 (pt) pirazol-4-n-alcoxicarboxamidas como microbiocidas
BRPI0917017A2 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
GB0811304D0 (en) Therapeutic agents
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0911118A2 (pt) composto e compisições como moduladores de atividade de gpr119
BRPI0907641A2 (pt) Piridinas fundidas ativas como inibidores de c-met
BRPI0920448A2 (pt) compostos spiro-oxindol e seu uso como agentes terapêuticos
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI0812411A2 (pt) Amidas de ácido pirazol carboxílico úteis como microbicidas
ATE523097T1 (de) Inertisierte entrappungsmaschine
EP2328875A4 (en) TARGETED NITROXIDE
GB0819593D0 (en) Therapeutic agents
GB0821693D0 (en) Therapeutic agents
GB0801081D0 (en) Therapeutic agents
LT3150178T (lt) Stimuliavimo aparatas
GB0801080D0 (en) Therapeutic agents
GB0812309D0 (en) Therapeutic agents
GB0805818D0 (en) Therapeutic agents
SMT201600041B (it) Agenti terapeutici 713
HRP20160577T1 (hr) Liječenje osteoartritisa
BRPI0811924A2 (pt) Derivados de butona úteis como agentes refrigerantes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.